Skip to main content
Premium Trial:

Request an Annual Quote

Perthera, Side-Out Foundation Partner to Advance Precision Oncology in Breast Cancer

NEW YORK – Holliston, Massachusetts-based Perthera and The Side-Out Foundation said on Thursday that they have partnered on a national research program to improve targeted treatment for advanced breast cancer and demonstrate the value of precision medicine for these patients.

Within the program, the advanced breast cancer-focused nonprofit and research organization, Side-Out, is providing philanthropic support to make molecularly informed treatments, including those in clinical trials, more accessible to breast cancer patients with the help of Perthera's multiomics precision oncology analysis platform. The partners hope to improve outcomes for advanced breast cancer patients, demonstrate the impact of precision oncology, accelerate clinical trial enrollment, and generate research publications that advance science.

Advanced breast cancer patients who have been molecularly profiled or plan to undergo testing will be eligible to enroll in the program no matter where they live or whether they have insurance. Upon enrollment, Perthera's clinical team will coordinate with the patients and their oncologists to ensure they have gotten the molecular testing necessary to personalize their care. Through the program, patients and their care teams will have access to Perthera's matched treatment recommendations and clinical trial matching services, as well as the opportunity to tap into Side-Out's financial support to ensure they can receive these treatments.

Within the program the partners will also collect patient outcomes data, which they hope will inform precision oncology-based breast cancer research. "Not only will we deliver our decision support and clinical trial matching to oncologists and patients, but through our outcomes capturing capabilities, we aim to build one of the world's most comprehensive breast cancer real-world evidence databases," Gary Gregory, Perthera's CEO, said in a statement.